Puma Biotechnology, Inc.
pumabiotechnology.comTotal trials
38
Active
3
Phase 3
2
Total enrollment
8,565
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Alisertib | — | — | — | — | — | 3 | |
| Paclitaxel | — | — | — | — | 5 | ||
| Endocrine therapy | — | — | — | — | — | 1 |
Next readouts
- 2027-04-30
- 2027-06-30
- 2028-03-31
Top conditions
- Healthy8
- Breast Cancer7
- Advanced Malignant Solid Tumors5
- Advanced Breast Cancer3
- Breast Neoplasms3
- Healthy Subjects3
- Neoplasms2
- Malignant Carcinoma1
Frequently asked questions about Puma Biotechnology, Inc.
- How many clinical trials does Puma Biotechnology, Inc. have on ClinicalTrials.gov?
- Puma Biotechnology, Inc. is listed as the lead sponsor on 38 clinical trials in ClinicalTrials.gov, 3 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Puma Biotechnology, Inc.'s trials are in Phase 3?
- 2 of Puma Biotechnology, Inc.'s trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Puma Biotechnology, Inc. focus on?
- Puma Biotechnology, Inc.'s most-studied conditions on ClinicalTrials.gov are Healthy, Breast Cancer, Advanced Malignant Solid Tumors, Advanced Breast Cancer, Breast Neoplasms.
- When are Puma Biotechnology, Inc.'s next clinical trial readouts?
- Puma Biotechnology, Inc. has 3 upcoming primary-completion readouts tracked here; the soonest is “A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer”, expected around 2027-04-30.